Prescription Required
Formulation: Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Tablet
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Jakavi (ruxolitinib) is a prescription medication used to treat certain blood and bone marrow disorders, including myelofibrosis and polycythemia vera. It is also used to treat certain forms of graft-versus-host disease (GVHD).
Jakavi contains ruxolitinib phosphate, an active ingredient belonging to a class of medications called Janus kinase (JAK) inhibitors.
JAK inhibitors work by blocking specific enzymes involved in blood cell production, inflammation, and immune system activity.
In certain blood disorders, these enzymes become overactive, causing the body to produce abnormal numbers of blood cells or release excessive inflammatory substances.
By reducing this activity, Jakavi helps control abnormal blood cell production, reduce enlarged spleen size, and relieve certain disease-related symptoms.
Jakavi is available as oral tablets in different strengths. Your healthcare provider will determine the appropriate treatment based on your diagnosis, blood cell counts, and response to previous medications.
Jakavi is used to treat adults with polycythemia vera (PV), a chronic blood disorder that causes the bone marrow to produce too many red blood cells.
Red blood cells carry oxygen throughout the body. However, when the body produces excessive numbers of these cells, the blood may become thicker than normal.
This can make circulation less efficient and increase the risk of blood clots, which may lead to serious complications such as stroke, heart attack, or deep vein thrombosis.
Polycythemia vera belongs to a group of conditions called myeloproliferative neoplasms, which affect how the bone marrow produces blood cells.
Many people with polycythemia vera have a mutation in the JAK2 gene that causes abnormal activation of cell-signalling pathways involved in blood cell production.
Common symptoms include:
Jakavi may be prescribed when previous treatment has not adequately controlled the condition or has caused side effects that make continued use difficult.
In Canada, Jakavi is indicated for adults with polycythemia vera who are resistant to or cannot tolerate a cytoreductive medication. In some other countries, the approved indication specifically refers to hydroxyurea.
Cytoreductive medications work by reducing the number of blood cells produced by the bone marrow.
Jakavi helps manage polycythemia vera by blocking JAK1 and JAK2 enzymes, which are involved in the signalling pathways that control blood cell production.
Treatment may help lower elevated hematocrit levels, reduce the need for frequent blood removal procedures called phlebotomies, and improve certain disease-related symptoms.
Hematocrit refers to the percentage of blood made up of red blood cells.
Controlling hematocrit is important because excessive red blood cell levels can increase the risk of blood clots.
Jakavi helps control polycythemia vera, but it does not permanently cure the condition.
Your healthcare provider will monitor your blood cell counts regularly to assess your treatment response and adjust your dosage when necessary.Â
Jakavi is also used to manage certain symptoms of primary myelofibrosis, a chronic bone marrow disorder that affects normal blood cell production.
Bone marrow is the soft tissue inside bones responsible for producing red blood cells, white blood cells, and platelets.
In people with myelofibrosis, abnormal bone marrow activity leads to the development of scar tissue, also called fibrosis.
As scarring increases, the bone marrow may become less effective at producing healthy blood cells.
This can cause anemia, fatigue, enlarged spleen, and other complications.
Primary myelofibrosis develops independently, rather than progressing from another blood disorder.
Possible symptoms include:
Jakavi helps reduce excessive JAK signalling associated with myelofibrosis.
By blocking JAK1 and JAK2 enzymes, the medication may decrease inflammatory activity and reduce certain abnormal signals involved in blood cell production.
This can help shrink an enlarged spleen and relieve symptoms such as abdominal discomfort, night sweats, itching, and fatigue.
Jakavi may also be prescribed for myelofibrosis that develops after polycythemia vera or essential thrombocythemia.
These conditions are known as post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Jakavi is not considered a cure for myelofibrosis and does not reliably reverse bone marrow scarring.
Your healthcare provider will monitor your blood counts because treatment can also reduce red blood cell and platelet levels, potentially causing anemia or thrombocytopenia.
Essential thrombocythemia (ET) is a chronic blood disorder that causes the bone marrow to produce too many platelets.
Platelets are small blood components that help form clots and stop bleeding after an injury.
Although platelets are necessary for normal blood clotting, excessive platelet production can increase the risk of blood clots and, in some cases, bleeding complications.
Essential thrombocythemia is another type of myeloproliferative neoplasm.
Some people with this condition have mutations involving JAK2, CALR, or MPL genes, which affect blood cell production.
Possible symptoms include:
Abnormal Bleeding: Bruising or bleeding complications in some individuals.
Jakavi has been studied in patients with essential thrombocythemia who did not respond adequately to or could not tolerate other treatments.
However, Jakavi is not specifically approved to treat essential thrombocythemia in Canada or the European Union.
Its use for essential thrombocythemia would therefore be considered off-label in these regions.
An important distinction is that Jakavi is approved to treat symptoms of post-essential thrombocythemia myelofibrosis, which is myelofibrosis that develops after essential thrombocythemia.
These are not the same diagnosis.
For patients with essential thrombocythemia, healthcare providers may recommend other treatments based on platelet counts, clotting risk, age, and medical history.
Jakavi should only be considered for this condition when a specialist determines that its use is appropriate.Â
Jakavi is also used to treat certain forms of graft-versus-host disease (GVHD), a serious complication that can develop after an allogeneic stem cell transplant.
An allogeneic stem cell transplant uses healthy blood-forming stem cells from another person, called a donor, to replace damaged or diseased bone marrow.
GVHD occurs when immune cells from the donor recognize the recipient’s healthy tissues as foreign and begin attacking them.
This immune reaction can cause inflammation and damage to organs such as the skin, liver, and digestive tract.
There are two main forms of GVHD.
Acute GVHD often develops during the early period following a stem cell transplant, although it can occur later.
Common symptoms include skin rashes, diarrhea, abdominal pain, nausea, and abnormal liver function.
Corticosteroids are commonly used as an initial treatment to reduce the immune system’s activity.
However, some people do not respond adequately to corticosteroids or cannot reduce their steroid dosage without symptoms returning.
Jakavi may be prescribed to manage acute GVHD in these situations.
In Canada, Jakavi is indicated for adults and children aged 12 years and older with acute GVHD that is resistant to or dependent on corticosteroid treatment.
Chronic GVHD may develop months or years after a stem cell transplant.
It can affect several organs and cause longer-lasting symptoms.
Possible symptoms include:
Jakavi may help control chronic GVHD by reducing excessive immune system signalling and inflammation.
In Canada, it is indicated for adults and children aged 12 years and older with chronic GVHD who have not responded adequately to corticosteroids or other systemic treatments.
Your healthcare provider will determine the appropriate treatment based on the type and severity of GVHD, previous treatments, and blood test results.Â
Jakavi contains ruxolitinib, a medication that blocks two enzymes called Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2).
These enzymes are part of a signalling system known as the JAK-STAT pathway.
The JAK-STAT pathway helps cells respond to chemical signals that regulate blood cell production, inflammation, and immune system activity.
When certain signals become overactive, they can contribute to abnormal blood cell production and excessive inflammation.
By blocking JAK1 and JAK2, Jakavi helps reduce these abnormal signals.
Inhibits JAK1 and JAK2 Enzymes
JAK1 and JAK2 are enzymes that help carry signals from the outside of a cell to its nucleus.
These signals influence how cells grow, divide, and respond to inflammation.
In certain blood disorders, JAK signalling becomes excessively active.
Jakavi blocks JAK1 and JAK2 activity, reducing the signals that contribute to disease symptoms.
This action helps control abnormal blood cell production and inflammation.
Regulates Blood Cell Production
Blood cells develop in the bone marrow through a process called hematopoiesis.
The body uses several chemical signals to control how many red blood cells, white blood cells, and platelets are produced.
In conditions such as polycythemia vera and myelofibrosis, these signals may become abnormal.
Jakavi reduces excessive JAK signalling, helping control some of the processes involved in abnormal blood cell production.
However, the medication can also suppress normal blood cell production.
For this reason, Jakavi may cause anemia, thrombocytopenia (low platelet counts), or neutropenia (low levels of certain white blood cells).
Regular blood tests are necessary to monitor these effects.
Reduces Inflammation
Inflammatory proteins called cytokines help the immune system communicate and respond to infections or injuries.
In some blood disorders and immune-related conditions, excessive cytokine activity contributes to ongoing inflammation.
This may cause symptoms such as fatigue, fever, night sweats, itching, and weight loss.
Jakavi reduces signalling from certain cytokines by blocking JAK1 and JAK2.
This may help relieve inflammatory symptoms associated with myelofibrosis and reduce excessive immune activity in GVHD.
Helps Reduce Enlarged Spleen Size
Some people with myelofibrosis or polycythemia vera develop an enlarged spleen, a condition called splenomegaly.
The spleen helps filter blood and remove old or damaged blood cells.
When normal bone marrow function becomes disrupted, the spleen may begin producing additional blood cells.
This can cause the organ to enlarge.
An enlarged spleen may lead to abdominal discomfort, pain beneath the left ribs, or feeling full after eating a small amount of food.
Jakavi may help reduce spleen enlargement in certain patients with myelofibrosis and polycythemia vera.
Reducing spleen size can relieve abdominal pressure and improve comfort during meals.
The time needed for Jakavi to produce noticeable benefits depends on the condition being treated and the individual’s response.
Some people with myelofibrosis may notice improvements in symptoms such as night sweats, itching, or abdominal discomfort during the first several weeks of treatment.
A reduction in spleen size may take longer and is usually assessed during follow-up examinations.
For polycythemia vera, your healthcare provider will monitor hematocrit levels and other blood test results to determine how well the medication controls your condition.
For graft-versus-host disease, treatment response depends on the severity of inflammation, the organs affected, and your response to previous therapies.
Jakavi is generally taken twice daily, although the prescribed dosage varies by condition and blood cell counts.
Do not increase your dosage if you do not notice immediate improvement.
Jakavi requires careful medical supervision because it affects blood cell production and immune system activity.
Your healthcare provider will usually recommend blood tests before treatment and at regular intervals afterward.
Jakavi may increase the risk of serious infections, including tuberculosis, shingles, and hepatitis B reactivation.
It may also cause low blood cell counts, making it important to report unusual bleeding, severe fatigue, fever, or other symptoms of infection.
Do not stop taking Jakavi suddenly without consulting your healthcare provider. Rapid discontinuation may cause symptoms to return or worsen, and some patients have experienced serious complications after stopping treatment.
Jakavi helps manage certain blood disorders and graft-versus-host disease by blocking JAK1 and JAK2 enzymes. It can help reduce disease-related symptoms, control elevated blood cell levels, and improve spleen enlargement, but it does not cure these conditions.
Jakavi is a prescription medication used to treat certain blood and bone marrow disorders, including myelofibrosis, polycythemia vera, and some forms of graft-versus-host disease (GVHD).
Jakavi belongs to a class of medications called Janus kinase (JAK) inhibitors. It works by blocking JAK1 and JAK2 enzymes, which are involved in blood cell production, inflammation, and immune system activity.
Jakavi is available as oral tablets in different strengths. The recommended dosage depends on your medical condition, blood cell counts, liver and kidney function, and response to treatment.
Jakavi tablets are typically taken twice daily, approximately 12 hours apart. However, some patients may require a different dosing schedule based on their medical needs.
Always follow your healthcare provider’s instructions and take the medication exactly as prescribed.
Follow these steps to take Jakavi correctly and safely:
Your healthcare provider may adjust your dosage based on your response to treatment and the results of your blood tests.
Taking Jakavi consistently helps maintain its effects on the JAK signalling pathways involved in abnormal blood cell production and inflammation.
For people with myelofibrosis, regular treatment may help reduce spleen enlargement and relieve symptoms such as abdominal discomfort, night sweats, and fatigue.
For people with polycythemia vera, Jakavi may help control elevated blood cell levels and reduce the need for certain additional treatments.
For patients with graft-versus-host disease, Jakavi helps reduce excessive immune system activity that can damage healthy tissues.
Missing doses frequently or changing your treatment schedule may reduce the medication’s effectiveness.
Use a medication reminder or establish a daily routine if you have difficulty remembering your doses.
Your healthcare provider may adjust your Jakavi dosage based on several factors.
Blood Cell Counts
Jakavi can reduce the number of red blood cells, white blood cells, and platelets in your bloodstream.
Your healthcare provider will regularly monitor your complete blood count (CBC) to determine whether the medication is affecting normal blood cell production.
If your platelet count, hemoglobin level, or certain white blood cell counts become too low, your healthcare provider may reduce your dosage or temporarily interrupt treatment.
Liver Function
The liver helps process Jakavi after it enters the bloodstream.
People with impaired liver function may process the medication more slowly, which can increase medication exposure.
Your healthcare provider may recommend a lower dosage or additional monitoring if you have liver disease.
Kidney Function
Kidney function may also affect how Jakavi and its metabolites are eliminated from the body.
People with significant kidney impairment may require dosage adjustments.
Patients receiving dialysis may need a different dosing schedule determined by their healthcare provider.
Medication Interactions
Certain medications can increase the amount of ruxolitinib in the bloodstream.
These include some antifungal medications, antibiotics, and other drugs that affect the enzymes responsible for metabolizing Jakavi.
Your healthcare provider may adjust your dosage when Jakavi is taken with certain interacting medications.
Do not start or stop another prescription medication without medical advice.
If you forget to take a dose of Jakavi, skip the missed dose and take your next dose at its regularly scheduled time.
Do not take an extra dose to replace the one you missed.
Do not take two doses together or increase your next dose to make up for the missed medication.
Taking more Jakavi than prescribed may increase the risk of side effects, including low blood cell counts.
For example, if you normally take Jakavi in the morning and evening but forget your morning dose, skip it and take your evening dose at the usual time.
If you miss several doses or are unsure how to continue your treatment, contact your healthcare provider or pharmacist.
The Canadian and European patient instructions recommend taking the next scheduled dose rather than making up a missed dose.Â
Do not stop taking Jakavi without consulting your healthcare provider.
Jakavi helps manage certain blood disorders and immune-related conditions, but stopping treatment may cause symptoms to return.
Some patients with myelofibrosis have experienced a rapid return of disease-related symptoms after discontinuing ruxolitinib.
In rare cases, serious complications involving inflammation, fever, breathing difficulties, or cardiovascular changes have occurred after treatment was stopped.
Your healthcare provider may recommend gradually reducing the dosage or temporarily interrupting treatment, depending on your condition.
If you experience significant side effects, contact your healthcare provider instead of changing your dosage independently.
Taking more Jakavi than prescribed may increase the risk of serious side effects.
An overdose may cause excessive suppression of blood cell production, increasing the risk of anemia, infection, and bleeding.
If you accidentally take more Jakavi than prescribed, contact your healthcare provider, poison control center, or an emergency department immediately, even if you do not notice symptoms.
Do not attempt to correct an overdose by making additional changes to your medication schedule without medical advice.
Contact your healthcare provider if you develop persistent fatigue, unusual weakness, dizziness, easy bruising, or unexpected bleeding while taking Jakavi.
Because Jakavi affects the immune system, it may increase your risk of certain infections. Report fever, chills, persistent coughing, painful urination, or other signs of infection promptly.
Seek emergency medical attention if you experience severe bleeding, significant breathing difficulties, chest pain, confusion, or other serious symptoms.
Jakavi works best when taken consistently according to your prescribed treatment plan. Taking the medication at regular times, attending scheduled blood tests, and reporting side effects can help your healthcare provider monitor treatment and make dosage adjustments when necessary.
Jakavi (Ruxolitinib Phosphate) is available in the following forms and strength:
Before taking Jakavi, tell your healthcare provider about any medical conditions, infections, allergies, or medications you are taking.
Jakavi is a prescription medication used to treat certain blood and bone marrow disorders, including myelofibrosis and polycythemia vera. It is also prescribed for certain forms of graft-versus-host disease (GVHD).
Jakavi belongs to a class of medications called Janus kinase (JAK) inhibitors. It works by blocking JAK1 and JAK2 enzymes, which help regulate blood cell production, inflammation, and immune system activity.
Although Jakavi can help control disease-related symptoms, it may also lower blood cell counts and weaken the body’s ability to fight infections.
Your healthcare provider will monitor your condition during treatment and may adjust your dosage based on your blood test results.
Jakavi should be used with caution in people with liver disease or reduced liver function.
The liver helps process ruxolitinib after it enters the bloodstream. When liver function is impaired, the medication may remain in the body at higher levels, increasing the risk of side effects.
Jakavi may also cause elevated liver enzymes, which can be detected through blood tests.
Elevated liver enzymes can sometimes indicate irritation or damage to liver cells.
In some patients, significant liver problems may develop, particularly when other medical conditions or medications affect liver function.
Possible symptoms of liver problems include:
Tell your healthcare provider if you have hepatitis, cirrhosis, or a history of abnormal liver function tests.
Your healthcare provider may recommend liver function tests before treatment and periodically afterward.
Patients with liver impairment may require a lower starting dosage or additional monitoring.
Contact your healthcare provider promptly if you develop yellowing of the skin, dark urine, or persistent abdominal pain.
Severe liver injury is not a common established effect of Jakavi, but serious liver complications may occur in some circumstances, including hepatitis B reactivation.
Jakavi may increase the risk of reactivating certain viral infections, including hepatitis B.
Hepatitis B is a viral infection that affects the liver and may cause inflammation, liver damage, or long-term liver disease.
Some people recover from hepatitis B but continue to carry inactive viral material in their bodies.
When the immune system becomes weakened, the virus may become active again. This is called hepatitis B reactivation.
Because Jakavi affects immune system signalling, it may reduce the body’s ability to keep certain infections under control.
Hepatitis B reactivation can cause liver inflammation and, in severe cases, liver failure.
Possible symptoms include:
Tell your healthcare provider if you have hepatitis B, have previously been treated for hepatitis B, or have been exposed to the virus.
Your healthcare provider may recommend hepatitis B testing before starting Jakavi.
If you have a history of hepatitis B, additional monitoring or antiviral treatment may be necessary.
Seek medical attention promptly if you develop symptoms of liver inflammation while taking Jakavi.
Do not stop or change your medication without consulting your healthcare provider.Â
People taking Jakavi may have an increased risk of developing certain types of non-melanoma skin cancer.
Non-melanoma skin cancer refers mainly to basal cell carcinoma and squamous cell carcinoma.
These cancers develop in skin cells and are often associated with long-term ultraviolet (UV) exposure.
Some patients treated with Jakavi have developed non-melanoma skin cancers, particularly those with a history of skin cancer or previous treatment with certain medications that affect the immune system.
Because Jakavi influences immune system activity, regular skin monitoring is important.
Possible warning signs include:
Your healthcare provider may recommend periodic skin examinations during Jakavi treatment.
You can also reduce UV exposure by using sunscreen, wearing protective clothing, and avoiding excessive direct sunlight.
Contact your healthcare provider if you notice new or changing skin lesions.
Early evaluation can help identify suspicious skin changes before they become more serious.Â
Tell your healthcare provider if you have heart disease, a history of blood clots, or other cardiovascular risk factors before taking Jakavi.
Important cardiovascular conditions include heart attack, stroke, and venous thromboembolism.
Venous thromboembolism refers to blood clots that form in veins, including deep vein thrombosis (DVT) and pulmonary embolism (PE).
Certain JAK inhibitors have been associated with increased risks of serious cardiovascular events, blood clots, and some cancers.
Health Canada has identified these risks as important safety concerns for the JAK inhibitor class, including Jakavi.
However, the evidence of increased heart attack or stroke risk is stronger for certain other JAK inhibitors than for ruxolitinib specifically. The risks should not be assumed to be identical across all medications in this class.
Your underlying blood disorder may also increase your risk of blood clots, making cardiovascular monitoring especially important.
Tell your healthcare provider if you have:
Possible symptoms of a blood clot or cardiovascular emergency include:
Your healthcare provider will assess your cardiovascular history and determine whether additional monitoring is necessary.
Seek emergency medical attention if you experience symptoms of a heart attack, stroke, or pulmonary embolism.Â
Jakavi may increase the risk of developing serious infections, including tuberculosis (TB).
Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis.
It most commonly affects the lungs but may also involve other organs.
Some people have latent tuberculosis, meaning the bacteria remain in the body without causing symptoms.
If the immune system becomes weakened, latent tuberculosis may become active.
Jakavi affects immune system signalling and may increase the risk of reactivating tuberculosis in susceptible individuals.
Possible symptoms of active tuberculosis include:
Tell your healthcare provider if you have previously had tuberculosis, have been exposed to someone with active TB, or have lived in an area where tuberculosis is common.
Your healthcare provider may recommend tuberculosis screening before starting Jakavi.
If latent tuberculosis is detected, appropriate treatment may be recommended before or during Jakavi therapy.
Jakavi should not be started in people with an active serious infection until the condition is appropriately managed.
Contact your healthcare provider promptly if you develop a persistent cough, fever, or unexplained weight loss during treatment.
Jakavi may increase the risk of herpes zoster infection, commonly called shingles.
Shingles is caused by reactivation of the varicella-zoster virus, the same virus responsible for chickenpox.
After a person recovers from chickenpox, the virus remains inactive in certain nerve cells.
The virus may reactivate later in life, particularly when immune system activity is reduced.
Because Jakavi affects immune signalling, some patients may become more susceptible to shingles.
Common symptoms include:
Shingles can sometimes cause complications, including persistent nerve pain called postherpetic neuralgia.
Tell your healthcare provider if you have previously experienced shingles or frequently develop viral infections.
Your healthcare provider may recommend vaccination before treatment when appropriate.
If you notice a painful blistering rash, contact your healthcare provider promptly.
Early antiviral treatment may reduce the severity and duration of shingles.
Jakavi should not be used during pregnancy or breastfeeding.
Ruxolitinib affects signalling pathways involved in cell growth, blood cell production, and immune system activity.
There is insufficient information from human studies to establish the safety of Jakavi during pregnancy.
Animal studies have shown harmful effects on developing offspring, raising concerns about possible risks to an unborn baby.
Tell your healthcare provider if you are pregnant, planning to become pregnant, or think you may be pregnant before starting Jakavi.
People who can become pregnant should use effective contraception during treatment, following their healthcare provider’s recommendations.
If you become pregnant while taking Jakavi, contact your healthcare provider promptly to discuss your treatment.
It is not known whether ruxolitinib passes into human breast milk. However, animal studies have shown that the medication and its metabolites can enter milk.
Because serious effects on a breastfed infant cannot be ruled out, breastfeeding is not recommended during Jakavi treatment.
Pregnancy and breastfeeding are listed as contraindications in European and UK Jakavi prescribing information.Â
Jakavi may interact with medications that affect how ruxolitinib is processed in the body.
The liver breaks down ruxolitinib mainly through an enzyme called CYP3A4, with CYP2C9 also contributing to its metabolism.
Certain medications can slow or increase the activity of these enzymes, changing the amount of Jakavi in your bloodstream.
These interactions may increase the risk of side effects or reduce the effectiveness of treatment.
Important interactions include:
Tell your healthcare provider about all prescription medications, over-the-counter drugs, vitamins, and herbal supplements you take.
Your healthcare provider may adjust your Jakavi dosage or recommend additional blood tests when certain medications are prescribed.
Do not start, stop, or change any medication without medical advice.Â
Tell your healthcare provider if you have kidney disease or reduced kidney function before taking Jakavi.
The kidneys help eliminate certain metabolites of ruxolitinib from the body.
People with significant kidney impairment may have increased exposure to these metabolites, which can affect treatment safety.
Patients with severe renal impairment may require a lower starting dosage.
Jakavi can also be used in certain patients receiving hemodialysis, but specialized dosing instructions are necessary.
The prescribed dosage depends on the condition being treated, kidney function, platelet count, and dialysis schedule.
Your healthcare provider may recommend:
Do not adjust your Jakavi dosage or dosing schedule yourself if you have kidney disease or receive dialysis.
Your healthcare provider will determine the appropriate regimen and monitor your response.Â
Do not stop taking Jakavi suddenly without consulting your healthcare provider.
Jakavi helps control inflammatory signalling and disease-related symptoms in people with myelofibrosis and certain other conditions.
After treatment is interrupted or discontinued, symptoms of myelofibrosis may return, sometimes within approximately one week.
In some patients, symptoms may become more severe after treatment stops.
Possible symptoms include:
Serious complications have occasionally been reported after Jakavi discontinuation, although the role of sudden withdrawal has not been fully established.
Your healthcare provider may recommend gradually reducing the dosage in certain situations.
However, tapering is not necessary or appropriate in every case, especially when treatment must be stopped urgently because of a serious complication.
Glucocorticoids are medications such as prednisone and dexamethasone that reduce inflammation and suppress immune system activity.
Some patients taking Jakavi, particularly those being treated for GVHD, may also receive glucocorticoids.
Stopping glucocorticoids suddenly after prolonged treatment may cause withdrawal symptoms or adrenal insufficiency.
Possible symptoms include severe fatigue, weakness, nausea, dizziness, and low blood pressure.
Glucocorticoid withdrawal is different from the return of symptoms that may occur after stopping Jakavi.
Your healthcare provider will determine how each medication should be reduced or discontinued.
Do not stop Jakavi or prescribed glucocorticoids without medical guidance.Â
Talk to your healthcare provider before receiving vaccines while taking Jakavi.
Jakavi affects immune system activity, which may influence how your body responds to certain vaccines.
Some vaccines contain weakened forms of living viruses or bacteria. These are called live attenuated vaccines.
Because Jakavi can suppress immune responses, live vaccines may pose additional risks during treatment.
Examples include:
Live vaccines should generally be avoided during Jakavi treatment unless a specialist determines that they are appropriate.
Non-live vaccines, such as injectable influenza vaccines and recombinant shingles vaccines, may be recommended depending on your medical history.
However, some patients may have a reduced immune response to vaccination while receiving Jakavi.
Your healthcare provider may review your vaccination history before starting treatment and recommend appropriate immunizations.
Do not receive a live vaccine without first consulting your healthcare provider.
Jakavi may reduce the number of red blood cells, white blood cells, and platelets in the bloodstream.
This is one of the most important safety precautions associated with ruxolitinib treatment.
Red blood cells carry oxygen, white blood cells help fight infections, and platelets help the blood clot.
When these blood cell levels become too low, serious complications may develop.
Potential effects include:
Your healthcare provider will perform a complete blood count before starting Jakavi and regularly during treatment.
Depending on the results, your healthcare provider may reduce your dosage, temporarily interrupt treatment, or recommend additional care.
Contact your healthcare provider promptly if you experience unusual bruising, persistent bleeding, fever, or significant fatigue.
This monitoring is essential because low blood cell counts may develop even before noticeable symptoms appear.Â
Contact your healthcare provider if you experience unusual fatigue, frequent infections, new skin lesions, persistent abdominal discomfort, or unexpected changes in your health while taking Jakavi.
Tell your healthcare provider if you have liver disease, kidney problems, hepatitis B, tuberculosis, a history of blood clots, or other cardiovascular conditions.
Seek prompt medical attention if you develop fever, painful shingles blisters, persistent coughing, unexplained bruising, or signs of liver problems.
Seek emergency medical attention if you experience severe bleeding, sudden chest pain, difficulty breathing, symptoms of a stroke, or serious signs of infection.
Jakavi can help manage myelofibrosis, polycythemia vera, and certain forms of graft-versus-host disease, but regular medical monitoring is essential. Blood tests, infection screening, medication reviews, and appropriate dosage adjustments help reduce the risk of serious treatment-related complications.
If you forget to take a dose of Jakavi, skip the missed dose and take your next dose at its regularly scheduled time. Jakavi is a prescription medication usually taken twice daily to treat certain blood disorders and forms of graft-versus-host disease (GVHD). Taking the medication consistently helps maintain its effects on blood cell production and immune system activity. Unlike some medications, Jakavi should not be taken as soon as you remember a missed dose. Instead, continue with your regular dosing schedule. For example, if you normally take Jakavi in the morning and evening but forget your morning dose, skip it and take your evening dose at the usual time. Do not take two doses together or increase your next dose to make up for the missed medication. Taking more Jakavi than prescribed may increase the risk of side effects, including anemia, low platelet counts, and other blood-related complications. If you frequently forget your medication, consider setting daily reminders or using a medication schedule. Contact your healthcare provider or pharmacist if you miss several doses or are unsure how to continue treatment.
Jakavi may begin improving certain disease-related symptoms within the first few weeks of treatment. However, the time needed to experience noticeable benefits varies depending on your medical condition, dosage, and individual response. Jakavi belongs to a class of medications called Janus kinase (JAK) inhibitors. It works by blocking JAK1 and JAK2 enzymes, which are involved in blood cell production, inflammation, and immune system activity. For people with myelofibrosis, Jakavi may help reduce symptoms such as night sweats, itching, fatigue, and abdominal discomfort during the early stages of treatment. Some patients may notice symptom improvements within several weeks, while a reduction in an enlarged spleen may take longer. For people with polycythemia vera, your healthcare provider will monitor red blood cell levels, hematocrit, and the need for phlebotomy procedures to evaluate treatment effectiveness. Patients receiving Jakavi for graft-versus-host disease may experience improvements in inflammation and other symptoms, depending on the severity of their condition and the organs affected. It may take several months to assess the full treatment response in some patients. Your healthcare provider will perform regular blood tests and medical examinations to determine how well Jakavi is working. Do not increase your dosage if you do not notice immediate improvements. Continue treatment as prescribed and report persistent or worsening symptoms to your healthcare provider.Â
The length of treatment with Jakavi depends on your medical condition, response to the medication, and whether you experience significant side effects. For people with myelofibrosis or polycythemia vera, Jakavi may be prescribed as a long-term treatment. These are chronic blood disorders that often require ongoing medical management. Jakavi helps control certain disease-related symptoms and abnormal blood cell activity, but it does not permanently cure these conditions. If the medication continues to provide benefits and your blood test results remain acceptable, your healthcare provider may recommend continuing treatment for several months or years. For graft-versus-host disease, treatment duration depends on the severity of the condition, response to therapy, and whether other immune-suppressing medications are still needed. Your healthcare provider will assess your progress and determine when treatment can be reduced or discontinued. Regular monitoring is important because Jakavi may cause low blood cell counts or increase the risk of infections. Your healthcare provider may adjust your dosage, temporarily interrupt treatment, or recommend another medication if the risks begin to outweigh the benefits. Do not stop taking Jakavi suddenly without medical advice. Stopping treatment may cause symptoms to return, and some patients have experienced serious complications after discontinuation.
Jakavi is generally described as a targeted therapy rather than traditional chemotherapy. Traditional chemotherapy medications often work by damaging or destroying rapidly dividing cells, including cancer cells and some healthy cells. Jakavi works differently. It targets specific enzymes called Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2). These enzymes help control blood cell production, inflammation, and immune system activity. In conditions such as myelofibrosis and polycythemia vera, abnormal JAK signalling contributes to excessive blood cell activity and disease-related symptoms. By blocking JAK1 and JAK2, Jakavi helps reduce abnormal signalling and control certain effects of these conditions. Unlike traditional chemotherapy, Jakavi does not primarily work by directly destroying rapidly dividing cells. However, it is still considered an antineoplastic medication and can cause serious side effects. These may include anemia, low platelet counts, reduced white blood cell levels, and increased susceptibility to infections. For this reason, patients taking Jakavi require regular blood tests and medical monitoring. Although Jakavi is not traditional cytotoxic chemotherapy, it is an important targeted treatment for certain blood disorders and immune-related conditions.
No, Jakavi does not cure myelofibrosis. However, it can help control symptoms, reduce spleen enlargement, and improve quality of life for some patients. Myelofibrosis is a chronic bone marrow disorder that causes scar tissue to develop inside the bone marrow. As scarring increases, the bone marrow may become less effective at producing healthy blood cells. This can lead to anemia, fatigue, an enlarged spleen, night sweats, bone pain, and unexplained weight loss. Jakavi works by blocking JAK1 and JAK2 enzymes, helping reduce abnormal inflammatory signalling associated with myelofibrosis. Treatment may provide several benefits, including reduced spleen size, less abdominal discomfort, fewer night sweats, and improved daily functioning. Some clinical studies have also suggested a possible survival benefit in certain patients. However, Jakavi does not reliably reverse bone marrow scarring or eliminate the underlying disease. An allogeneic stem cell transplant is currently the main treatment with the potential to cure myelofibrosis in selected patients, although it carries significant risks and is not suitable for everyone. Your healthcare provider will consider your age, overall health, disease severity, and treatment goals when recommending the most appropriate treatment. Jakavi helps manage myelofibrosis rather than permanently cure it. Regular blood tests, symptom monitoring, and follow-up appointments are important for evaluating your response.
Yes, Jakavi may be prescribed to children for certain forms of graft-versus-host disease (GVHD), depending on their age and the prescribing regulations in their country. However, Jakavi is not approved for treating myelofibrosis or polycythemia vera in children. These indications are limited to adults. Graft-versus-host disease is a serious condition that may occur after an allogeneic stem cell transplant. It develops when immune cells from the donor attack healthy tissues in the recipient’s body. Jakavi helps reduce the excessive immune activity and inflammation associated with GVHD. In the European Union, Jakavi is approved for treating acute GVHD in children aged 28 days and older and chronic GVHD in children aged six months and older when certain previous treatments have not worked adequately. In the United Kingdom, product-specific approved age ranges may differ. Other countries may also have different pediatric indications. Children receiving Jakavi require careful medical supervision because the medication can reduce blood cell counts and increase the risk of infections. Your healthcare provider will determine the appropriate dosage based on the child’s age, body size, medical condition, blood test results, and response to treatment. Children may receive Jakavi tablets or an oral solution, depending on the formulation available and their ability to swallow tablets. Regular blood tests are necessary to monitor treatment effectiveness and identify possible side effects. Do not give Jakavi to a child unless it has been specifically prescribed by a healthcare provider experienced in treating the child’s condition.Â
| Generic name: | ruxolitinib phosphate |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 5mg, 10mg, 15mg, 20mg |
| Quantities Available: | 56 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Jakavi (ruxolitinib phosphate) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Jakavi is commonly prescribed in dosages of 5 mg, 10 mg, 15 mg, or 20 mg, taken twice daily. For a 90-day supply, this means you would order 180 tablets of the prescribed dosage (90 days x 2 tablets per day).
No, we do not sell ruxolitinib phosphate directly on our website. However, you can still enjoy low prices on Jakavi, which contains ruxolitinib phosphate as an active ingredient. To purchase Jakavi, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship Jakavi (ruxolitinib phosphate) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Jakavi (ruxolitinib phosphate). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Jakavi (ruxolitinib phosphate).
REVIEWS